Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Roche and Illumina sign 15-year NGS testing deal in oncology

Executive Summary

Roche Diagnostics Corp. and Illumina Inc. signed a 15-year, nonexclusive deal aimed at expanding the use of next-generation sequencing (NGS) testing in oncology. The overall goal is to broader access to NGS diagnostics on Illumina’s platforms for labs, clinicians, and patients.

Deal Industry
  • In Vitro Diagnostics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register